---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-220671"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2026-05-13T12:15:06+00:00"
generated_at: "2026-05-13T12:23:36.871699+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma appoints Donn Casale as President effective June 1, 2026

## Summary
- Donn Casale, 53, most recently Chief Commercial Officer at Dynavax (acquired by Sanofi), joins as President.
- Casale will receive an annual base salary of $575,000 and target annual discretionary bonus of 45% of base.
- Stock option grant valued at ~$6M under 2020 Equity Incentive Plan; exercise price = grant date closing price.
- Option vests 25% after one year, then monthly over 36 months; subject to continued employment.
- He replaces Richard Lowenthal as President; Lowenthal remains CEO.

## SEC filing metadata
- accession: 0001193125-26-220671
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2026-05-13T12:15:06+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312526220671/0001193125-26-220671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312526220671/d10320d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-220671
- JSON: https://secwatch.observer/filing/0001193125-26-220671.json
- Plain text: https://secwatch.observer/filing/0001193125-26-220671.txt

## Key facts
- Executive change
  Donn Casale was appointed as President at ARS Pharmaceuticals, Inc..
  - Action: appointed
  - Role: President
  source text: appointed Donn Casale as the Company’s President effective as of the date he commences employment with the Company, which date is expected to be June 1, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312526220671/0001193125-26-220671-index.htm
- Executive change
  Richard Lowenthal changed role as President at ARS Pharmaceuticals, Inc..
  - Role: President
  source text: Mr. Lowenthal previously served as President.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312526220671/0001193125-26-220671-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.